Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
ANI's Rare Disease/Brands expansion includes ophthalmic therapies ILUVIEN and YUTIQ acquired via Alimera, marking Ophthalmic Drugs as a direct product category.
|
$1.76B |
$81.28
-0.29%
|
|
MAZE
Maze Therapeutics, Inc.
Maze develops small molecule therapeutics, including MZE829 and MZE782, which are oral small molecule treatments for renal/cardiovascular/metabolic diseases.
|
$1.74B |
$40.09
+0.96%
|
|
BHE
Benchmark Electronics, Inc.
Manufactures Medical Device Components for use in regulated medical devices.
|
$1.69B |
$45.64
-3.31%
|
|
HROW
Harrow Health, Inc.
Direct ophthalmic drug products (VEVYE, IHEEZO, TRIESENCE, BYQLOVI) are core branded ophthalmic pharmaceuticals.
|
$1.69B |
$44.24
-3.19%
|
|
UFPT
UFP Technologies, Inc.
Design and manufacture of customized components and subsystems used in medical devices (foams, films, plastics, fabrics, die-cut parts, and assembly).
|
$1.68B |
$218.36
+0.25%
|
|
PAHC
Phibro Animal Health Corporation
Vaccines are explicitly listed as a pillar of the Animal Health segment.
|
$1.65B |
$40.30
-0.91%
|
|
AZTA
Azenta, Inc.
Azenta's automated sample storage and cryogenic systems fall under Medical Devices & Biometrics.
|
$1.61B |
$34.21
-2.48%
|
|
TWFG
TWFG, Inc. Common Stock
Distributes health insurance products.
|
$1.60B |
$28.41
-0.33%
|
|
BCRX
BioCryst Pharmaceuticals, Inc.
ORLADEYO is BioCryst's flagship oral small-molecule therapy for hereditary angioedema, a core product.
|
$1.59B |
$7.53
-0.86%
|
|
ENOV
Enovis Corporation
Directly produces orthopedic devices and implants used in reconstructive surgery.
|
$1.58B |
$27.93
+0.94%
|
|
TSHA
Taysha Gene Therapies, Inc.
TSHA-102 is an AAV9-based gene therapy product directly developed by Taysha for Rett syndrome.
|
$1.57B |
$5.81
+0.87%
|
|
AGIO
Agios Pharmaceuticals, Inc.
Lead assets PYRUKYND (mitapivat) and tebapivat are oral small-molecule PK activators targeting red blood cell metabolism in rare hematologic diseases, representing Agios's core product strategy.
|
$1.56B |
$26.25
-2.25%
|
|
ZBIO
Zenas BioPharma, Inc.
Company focuses on immunology-based therapeutics for autoimmune diseases.
|
$1.55B |
$36.75
+12.76%
|
|
NEO
NeoGenomics, Inc.
They provide comprehensive laboratory testing services and advisory support for oncology diagnostics.
|
$1.54B |
$11.62
-2.56%
|
|
TRVI
Trevi Therapeutics, Inc.
Trevi Therapeutics develops Haduvio, an oral small molecule therapeutic (nalbuphine ER) for chronic cough.
|
$1.54B |
$12.52
-0.75%
|
|
COLL
Collegium Pharmaceutical, Inc.
Jornay PM, Belbuca, Xtampza ER, and Nucynta are all oral small-molecule therapeutics, representing major product categories in Collegium's portfolio.
|
$1.53B |
$48.71
-0.61%
|
|
TNDM
Tandem Diabetes Care, Inc.
Tandem Diabetes Care manufactures insulin pumps (medical devices) and biometric sensing data integration, a core medical device product line.
|
$1.53B |
$22.52
+1.85%
|
|
ARDX
Ardelyx, Inc.
Ardelyx's core offerings are oral, small-molecule therapeutics (IBSRELA and XPHOZAH) based on tenapanor.
|
$1.49B |
$6.01
-3.06%
|
|
NEOG
Neogen Corporation
MDS pathogen detection platform and Petrifilm-based environmental testing are diagnostic equipment offerings.
|
$1.49B |
$7.05
+2.99%
|
|
UPB
Upstream Bio, Inc.
Verekitug is a monoclonal antibody therapeutic targeting the TSLP receptor, directly aligning with Monoclonal Antibody Therapeutics.
|
$1.47B |
$29.13
+7.10%
|
|
RLAY
Relay Therapeutics, Inc.
Directly develops oncology therapies (lead asset RLY-2608) and precision medicine leveraging its platform.
|
$1.46B |
$8.54
+0.77%
|
|
NRIX
Nurix Therapeutics, Inc.
Nurix's pipeline is oncology-focused with BTK/BRAF degraders and IRAK4 degrader in collaboration, aligning with Biotech - Oncology.
|
$1.45B |
$18.77
-1.26%
|
|
NVCR
NovoCure Limited
NovoCure's TTFields cancer therapy device (Optune) is a medical device sold to treat cancer, fitting the Medical Devices & Biometrics category.
|
$1.45B |
$13.01
+0.31%
|
|
FTRE
Fortrea Holdings Inc.
Fortrea operates as a standalone contract research organization providing outsourced clinical development services.
|
$1.45B |
$16.02
-0.22%
|
|
AHCO
AdaptHealth Corp.
Direct provider of Home Health & Hospice services and in-home patient care.
|
$1.39B |
$10.38
+1.12%
|
|
AXGN
AxoGen, Inc.
Axogen's Avance Nerve Graft and Axoguard nerve-repair products are surgical devices used in peripheral nerve repair.
|
$1.37B |
$29.20
-1.93%
|
|
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
Core product is Cardiology devices: wearable defibrillator (ASSURE WCD) and related cardiac therapy platform.
|
$1.36B |
$27.41
+3.49%
|
|
DNTH
Dianthus Therapeutics, Inc.
Lead product is a monoclonal antibody therapeutic targeting active C1s, a core product category.
|
$1.35B |
$40.95
-2.31%
|
|
CLOV
Clover Health Investments, Corp.
Clover Health operates Medicare Advantage plans and provides health insurance benefits.
|
$1.34B |
$2.62
-0.19%
|
|
SDGR
Schrödinger, Inc.
The company operates a proprietary drug discovery pipeline with programs in oncology, aligning with Biotech - Oncology.
|
$1.34B |
$18.11
-0.58%
|
|
ASTH
Astrana Health, Inc.
Astrana operates outpatient clinics and ambulatory surgical centers, i.e., care delivery services.
|
$1.32B |
$23.86
+6.21%
|
|
ACHC
Acadia Healthcare Company, Inc.
ACHC is a pure-play behavioral health provider delivering inpatient and outpatient mental health and substance use treatment services.
|
$1.31B |
$14.38
+1.09%
|
|
TDOC
Teladoc Health, Inc.
Integrated Care delivers virtual medical, mental health, and chronic condition management services.
|
$1.31B |
$7.37
+0.34%
|
|
CTS
CTS Corporation
CTS targets medical end-markets with diagnostic/sensor applications; tagged under Medical Devices & Biometrics.
|
$1.30B |
$44.37
+0.54%
|
|
PHVS
Pharvaris N.V.
Pharvaris' lead program deucrictibant is an oral small-molecule therapeutic targeting Bradykinin B2 receptor for HAE/AAE, fitting the 'Oral Small Molecule Therapeutics' category.
|
$1.30B |
$24.39
+2.05%
|
|
BBNX
Beta Bionics, Inc.
Core product is a medical device (iLet Bionic Pancreas) and related biometrics in diabetes care.
|
$1.29B |
$29.25
-1.58%
|
Showing page 12 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
